Multivariate analyses: baseline statin users versus non-users*
| Outcome | Multivariate analyses (statin users vs non-users) | ||
|---|---|---|---|
| HR | 95% CI | p Value | |
| Disease progression† | 0.75 | 0.52 to 1.07 | 0.1135 |
| Mortality | |||
| All-cause | 0.54 | 0.24 to 1.21 | 0.1369 |
| IPF-related | 0.36 | 0.14 to 0.95 | 0.0393 |
| FVC | |||
| Absolute decrease ≥10% | 0.81 | 0.47 to 1.40 | 0.4533 |
| Relative decrease ≥10% | 0.90 | 0.59 to 1.38 | 0.6262 |
| Absolute decrease ≥5% | 0.97 | 0.68 to 1.40 | 0.8805 |
| Relative decrease ≥5% | 0.91 | 0.66 to 1.25 | 0.5548 |
| Death or absolute FVC decrease ≥10% | 0.71 | 0.48 to 1.07 | 0.1032 |
| Death or 6MWD decrease ≥50 m | 0.69 | 0.48 to 0.99 | 0.0465 |
| Hospitalisation | |||
| All-cause | 0.58 | 0.35 to 0.94 | 0.0289 |
| Respiratory-related‡ | 0.44 | 0.25 to 0.80 | 0.0063 |
*Patients with missing baseline data were excluded from relevant analyses.
†Defined as ≥10% decrease in per cent predicted FVC, ≥50 m decline in 6MWD or death.
‡Hospitalisation in which the primary reason for admission was determined to be respiratory-related by a blinded clinical investigator.
6MWD, 6-minute walk distance; IPF, idiopathic pulmonary fibrosis.